Cdk4/6 Inhibitor

Cell cycle inhibitors - CDK4/6 inhibitors

Science in Motion

The Biological Rationale for CDK4/6 Inhibitors

The use of frontline CDK4/6 inhibitors + endocrine therapy in metastatic breast cancer

CDK 4/6 Inhibitors for Patients with Recurrent ER+/HER2- Breast Cancer: 2023 Best of Breast

Total Health | Oncology

Current state of CDK4/6 inhibitors in metastatic HER2-negative breast cancer

HR+ Breast Cancer: Differences Between CDK4/6 Inhibitors

Unmet needs and CDK4/6 inhibitors in HR+/HER2- early breast cancer

Breast Cancer Breakthroughs Episode 10: Top Takeaways from ASCO 2024

Susan G. Komen®

CDK4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer

Mechanistic Activity and Development History of CDK 4/6 Inhibitors

Understanding Abemaciclib: A New CDK4/6 Inhibitor

Investigating mechanisms of resistance to CDK4/6 inhibitors

Benefits and Challenges of CDK4/6 Inhibitors

Expert report on tackling resistance to CDK4/6 inhibitors in ER+/HER2-metastatic breast cancer

European Society for Medical Oncology (ESMO)

What is the role of CDK4/6 inhibitors in early breast cancer?

CDK 4/6 Inhibitors in Metastatic Breast Cancer

Case 2: Choosing a CDK4/6 Inhibitor in ER+ Breast Cancer

Targeted Oncology

Overcoming resistance to CDK4/6 inhibitors in ER+ breast cancer via ctDNA

Patients’ Perspectives on CDK4/6 Inhibitors

Remaining questions on the use of frontline CDK4/6 inhibitors + endocrine therapy